Phase II Trial of Docetaxel, Oxaliplatin, and Fluorouracil for Inoperable Malignant Bowel Obstruction in Gastric and Gastroesophageal Junction Adenocarcinoma

What this Trial Is About

Researchers are evaluating a combination of three chemotherapy drugsdocetaxel, oxaliplatin, and fluorouracilfor treating gastric cancer patients who have peritoneal carcinomatosis and inoperable malignant bowel obstruction. This phase II, multi-center, non-randomized trial includes three groups based on previous treatments first-line, second-line, and third- or later-line therapies. The main goal is to see if this drug regimen can clear bowel obstruction in these patients. Participants receive docetaxel, oxaliplatin, and fluorouracil in repeated 4-week cycles. Docetaxel is given intravenously on days 1, 8, and 15 oxaliplatin on days 1 and 15 and fluorouracil continuously over 24 hours on days 1, 8, and 15. Each of the three groups follows the same drug schedule but differs by prior chemotherapy history. Treatment continues with cycles repeating every 4 weeks. During the study, participants will be monitored for bowel obstruction clearance rates at 30 and 60 days, time to clearance, and how long the clearance lasts up to 2 years. Safety is tracked by recording adverse events over 2 years. Overall survival and quality of life measured by a specific questionnaire are also assessed. Participants will have regular clinical evaluations and laboratory tests throughout the study period, which runs until mid-2028.

Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction